Sage Therapeutics has been granted an FDA Fast Track designation for SAGE-217 in major depressive disorder.

The steroid modulates synaptic and extrasynaptic receptors, part of the inhibitory signaling pathway of the brain and central nervous system, and contributes significantly to regulating CNS function.

SAGE-217 is currently in Phase II development in both mood and movement disorders, with four Phase II clinical programs underway.